GW Pharmaceuticals keen on $150m US offering
Developer of cannabinoid therapies GW Pharmaceuticals announced on Wednesday that it intends to sell, subject to market and other conditions, $150m of American Depositary Shares representing ordinary shares of GW on the NASDAQ Global Market, in an underwritten US public offering.
FTSE AIM 100
3,517.21
08:35 14/11/24
n/a
n/a
FTSE AIM 50
3,949.48
08:35 14/11/24
n/a
n/a
FTSE AIM All-Share
728.67
08:35 14/11/24
n/a
n/a
GW Pharmaceuticals
735.00p
16:34 02/12/16
2.87%
20.50p
Gw Pharmaceuticals Plc - American Depositary Shares
$0.00
19:31 08/12/22
0.00%
$0.00
Pharmaceuticals & Biotechnology
19,674.02
08:34 14/11/24
0.34%
67.01
The AIM-traded firm said it expects to grant the underwriters a 30-day option to purchase up to an additional $22.5m of shares at the offering price.
“There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering,” GW’s board cautioned in a statement.
“The price for the offering has not yet been determined.”